Meet Nicholas Short, M.D.
Nicholas James Short, MD
Department of Leukemia, Division of Cancer Medicine
About Dr. Short
I am a clinical and translational investigator in adult acute leukemias, with a particular emphasis on the prognostic and therapeutic impact of measurable residual disease (MRD) and the development of phase I and II investigator-initiated clinical trials of novel agents and combinations for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). My major contributions to leukemia research include: developing new immunotherapy-based frontline regimens in Philadelphia chromosome-negative B-cell ALL, developing chemotherapy-free regimens in Philadelphia chromosome-positive ALL, establishing the clinical utility of high-sensitivity next-generation sequencing-based MRD assays in ALL, developing novel MRD-directed therapies in AML and ALL, and developing novel regimens for older adults with FLT3-mutated AML. I serve as principal investigator or co-principal investigator on over a dozen phase I and II clinical trials and have authored over 250 peer-reviewed manuscripts in the field of leukemia, including over 50 first-author publications, include papers in Lancet, Journal of Clinical Oncology, JAMA Oncology, Blood, and Cancer Discovery. For my clinical and translational accomplishments in the field of leukemia, I have been awarded the ASCO Young Investigator Award and the ASH Junior Faculty Scholar in Clinical Research.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Interests
Education & Training
Degree-Granting Education
| 2022 | The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, US, M.S. in Biomedical Sciences |
| 2011 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2006 | Rice University, Houston, Texas, US, BA in Philosophy |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2017 | Hematology, American Board of Internal Medicine |
| 2017 | Medical Oncology, American Board of Internal Medicine |
| 2017 | Texas Medical Board |
| 2014 | Internal Medicine, American Board of Internal Medicine |
| 2013 | Massachusetts Board of Registration in Medicine |
Experience & Service
Extramural Institutional Committee Activities
Chair, Scientific Review Committee (SRC), The University of Texas MD Anderson Cancer Center, 2025 - Present
Core Development Lead, ALL and AML Algorithm, The University of Texas MD Anderson Cancer Center, 2022 - Present
Reviewer, Institutional Research Grant Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Department of Biostatistics New Faculty Selection Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Faculty Judge, Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Faculty Lecturer, Comprehensive Board Review in Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, Scientific Review Committee (SRC), The University of Texas MD Anderson Cancer Center, 2018 - 2025
Core Development Team Leader, Tumor Lysis Syndrome Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present
Editorial Activities
Board Member, American Journal of Hematology, 2023 - Present
Board Member, Cancer, 2022 - Present
Board Member, Expert Opinion on Pharmacotherapy, 2021 - Present
Associate Editor, Frontiers in Oncology, 2021 - Present
Board Member, Acta Haematologica, 2020 - Present
Board Member, Frontiers in Oncology (Hematologic Malignancies section), 2020 - Present
Board Member, Journal of Hematology & Oncology, 2019 - Present
Honors & Awards
| 2024 | Teacher of the Year, Division of Cancer Medicine/Oncology Fellowship, The University of Texas MD Anderson Cancer Center |
| 2019 | Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology |
| 2019 | Junior Faculty Scholar Award in Clinical Research, American Society of Hematology |
| 2018 | Paul Calabresi Clinical Oncology Scholar, K12 Award |
| 2017 | Career Enhancement Award, Leukemia SPORE |
| 2017 | Merit Award, American Society of Clinical Oncology |
| 2017 | Next Gen Innovator, HemOnc Today |
| 2017 | Shannon Timmins Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center |
| 2017 | Young Investigator Award, American Society of Clinical Oncology |
| 2016 | Future Leaders in Hematology Award, Celgene |
| 2016 | Kimberly Patterson Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center |
| 2016 | Young Investigator Award, American Journal of Hematology |
| 2015 - 2016 | Abstract Achievement Award, American Society of Hematology |
| 2014 | Certificate for Excellence in Tutoring, Harvard Medical School |
| 2011 | Harry and Rose Caplovitz Internal Medicine Award, Baylor College of Medicine |
| 2011 | Stanley W. Olson Award for Academic Excellence and Service, Baylor College of Medicine |
| 2010 | Member, Alpha Omega Alpha Honor Society |
| 2010 | Michael E. DeBakey Scholar, Baylor College of Medicine |
| 2009 | Highest Honor for Pre-Clinical Academic Performance, Baylor College of Medicine |
| 2007 | Member, Phi Beta Kappa Honor Society |
| 2007 | Outstanding Premedical Student, John P. McGovern |
| 2003 - 2007 | Medical Scholar, Rice University/Baylor College of Medicine |
| 2003 - 2007 | Trustee Distinguished Scholar, Rice University |
| 2003 - 2005 | Century Scholar, Rice University |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. “Unanswered Questions in Frontline Treatment of B-cell ALL: 2025 Edition”. Invited. HemOnc Pulse. Austin, Texas, US.
National Presentations
- 2025. “State-of-the-Art Treatment of B-cell ALL in 2025”. Invited. UT Austin Pediatric Oncology Grand Rounds. Virtual, US.
- 2025. "Should the Initial Therapy for FLT3-Mutant AML be Aza + Ven + FLT3i or Intensive Chemotherapy + FLT3i?". Invited. Acute Leukemia Forum. La Jolla, CA, US.
- 2024. “Frontline Treatment of ALL in 2024”. Invited. Louisville Hematology Highlights Symposium. Louisville, TN, US.
- 2024. "MRD as an Endpoint in Clinical Trials". Invited. The International Workshop on Acute Leukemia (iwAL). Phoenix, AZ, US.
- 2024. "Triplet Therapy for Older Patients with AML Unfit for Intensive Chemotherapy". Invited. 24th Annual Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies. Hilton Head, SC, US.
- 2023. "Chemotherapy-free Treatment of Ph+All". Invited. MD Anderson Scripps Cancer Center. La Jolla, CA, US.
- 2022. “MRD in AML”. Invited. PACE Program – Practical Approach of MDS and AML Treatment in 2022,. Houston, TX, US.
- 2022. “Managed Care Considerations in the Treatment and Management of Acute Myeloid Leukemia (AML): Optimizing Decision-Making Strategies for Improved Clinical and Economic Outcomes,”. Invited. 2022 Fall Managed Care Forum. Las Vegas, NV, US.
- 2022. “Treatment of Relapsed/Refractory ALL”. Invited. NCCN 2022 Annual Congress: Hematological Malignancies. New York, NY, US.
- 2022. “Treatment of Ph+ ALL in Adults: Moving Toward Chemotherapy-Free Regimens,” 3rd Colloquium of Acute Leukemia and Myelodysplastic Syndrome". Invited. (CLAS). Virtual, US.
- 2022. “Transplant for Ph+ ALL in First Remission is No Longer Standard of Care.”. Invited. Kuwait Best of ASH 2021. Virtual, US.
- 2022. “Ph+ ALL: Post-Remission and Maintenance Treatment for Non-Transplanted Patients”. Invited. European School of Haematology (ESH). Virtual, US.
- 2021. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Conference. American Society of Hematology.
- 2021. "State-of-the-Art Therapy for Acute Lymphoblastic Leukemia". Invited. Montefiore Einstein Cancer Center.
- 2021. "Acute Lymphoblastic Leukemia: Cytogenetic and Molecular Alterations and the Rationale for Treatment Selection". Invited. Cvent.
- 2021. "Next Generation TKIs for Ph+ ALL". Invited. European School of Haematology (ESH).
- 2020. Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. Conference. American Society of Hematology, US.
- 2020. A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy. Conference. American Society of Hematology, US.
- 2020. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Conference. American Society of Hematology, US.
- 2020. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. Conference. American Society of Hematology, US.
- 2020. "Immune vs. Chemotherapy in ALL". Invited. CLAS - Coloquio de Leucemias Agudas y Sindrome Mielodisplasico.
- 2019. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Conference. American Society of Hematology. Orlando, FL, US.
- 2019. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Conference. American Society of Hematology. Orlando, FL, US.
- 2019. Achievement of Complete Remission (CR) with Measurable Residul Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Conference. American Society of Hematology. Orlando, FL, US.
- 2018. "Scouting for New Players: Future Directions in ALL". Invited. American Society of Hematology Annual Meeting Satellite Symposium. San Diego, CA, US.
- 2018. "MD Anderson Clinical Trials in ALL". Invited. Society for Adolescent and Young Adult Oncology Leukemia Symposium. Newport Beach, CA, US.
- 2017. "Ph + ALL: What's New?" Excellence in Acute Lymphoblastic Leukemia Treatment Transatlantic (ExALLt). Invited. "Ph + ALL: What's New?" Excellence in Acute Lymphoblastic Leukemia Treatment Transatlantic (ExALLt). Houston, TX, US.
International Presentations
- 2025. "Frontline Treatment of Ph+ ALL and the Emerging Role of Chemotherapy-Free Regimens. Invited. 3rd SOHO - Israel Meeting and The Davidoff Conference: State of the Art & Next Questions. Tel Aviv, IL.
- 2025. “Breaking Barriers in B-cell ALL: Advancing Frontline Therapy for Better Patient Outcomes”. Invited. Joint Annual Congress of HST and TBMT. Taipei, TW.
- 2025. "Special Education Session: Next Generation Clinical Sequencing and MRD Evaluation". Invited. American Society of Hematology (ASH). Yokohama, JP.
- 2024. “Immunotherapy in Adults with ALL: A Focus on Safety”. Invited. Agrupación Mexicana para el Estudio de la Hematología (AMEH). Virtual, MX.
- 2024. "Chemotherapy- Free Regimens for Philadelphia Chromosome Positive (Ph+) ALL.". Invited. The 86th Annual Meeting of JSH. Kyoto, JP.
- 2022. “Ponatinib Combination Strategies in Ph+ ALL”. Invited. International Workshop on Acute Leukemias 2022. Nice, FR.
- 2022. “Optimization of Treatment for Adults with Newly Diagnosed ALL”. Invited. 8th Amgen Medical Excellence Summit (CEMA 2022). Cancun, MX.
- 2020. "Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Invited. International Academic Oncology Virtual Meeting, Instituto Nacional de Cancerologia – Mexico, MX.
- 2019. "Optimizing the Use of FLT3 Inhibitors in AML". Invited. The European Congress on Leukemias: Between Cutting Edge and Grey Zone Controversies. Vienna, AU.
Formal Peers
- 2023. "Frontline Treatment of Adult ALL in 2023". Invited. New York, NY, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Advancing TGFâ-Resistant CAR-NK Cell Therapy for Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | PAR-25-081 |
| Date: | 2025 - 2027 |
| Title: | CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms |
| Funding Source: | FDA |
| Role: | PI |
| ID: | FP00025281 |
| Date: | 2025 - 2028 |
| Title: | Development of cellular therapy for CMML and the Immune landscape of response and resistance Major goals: Enroll patients, collect and distribute research samples for this novel CAR T-cell trial. Oversee our team of research nurses, data coordinators and laboratory personnel |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00025247 |
| Date: | 2025 - 2028 |
| Title: | CD4CAR T CELL THERAPY FOR AML |
| Funding Source: | Indiana University |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | PA-20-185 |
| Date: | 2023 - 2026 |
| Title: | Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML), Break Through Cancer |
| Funding Source: | Break Through Cancer |
| Role: | Co-PI |
| ID: | FP00018527 |
| Date: | 2020 - 2022 |
| Title: | Non-Invasive Monitoring of Measurable Residual Disease in Patients with Acute Myeloid Leukemia Using Circulating Cell-Free DNA |
| Funding Source: | IRG - Internal Research Grant |
| Role: | PI |
| ID: | RCTS#58881 |
| Date: | 2019 - 2022 |
| Title: | Paul Calabresi Clinical Oncology Award |
| Funding Source: | NIH/NCI |
| Role: | Faculty Scholar |
| ID: | K12-CA088084-19 |
| Date: | 2019 - 2022 |
| Title: | A phase II study of azacitidine, venetoclax and pevonedistat in adults with newly diagnosed secondary or therapy-related AML |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | Digital Droplet PCR of Somatic Mutations as a Sensitive Method to Improve Minimal Residual Disease Detection and Risk Stratification in Acute Myeloid Leukemia |
| Funding Source: | Leukemia SPORE Career Enhancement Award |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | Improving Prediction of Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Next-Generation Sequencing |
| Funding Source: | Conquer Cancer Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, Loghavi S, Nasr L, Haddad FG, Senapati J, Garris R, Takahashi K, Jabbour E. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol 18(1):55, 2025. e-Pub 2025. PMID: 40369607.
- Short NJ, Wierzbowska A, Cluzeau T, Laribi K, Recher C, Czyz J, Ochrem B, Ades L, Gallego-Hernanz MP, Heiblig M, Audisio E, Zarzycka E, Li S, Ferenc N, Yeh T, Faller DV, Sedarati F, Papayannidis C. Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma:1-11, 2024. e-Pub 2024. PMID: 39606906.
- Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Short, NJ, Jabbour, EJ, Nasr, L, Jain, N, Haddad, FG, Issa, GC, Sasaki, K, Senapati, J, Kebriaei, P, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. American journal of hematology 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
- Short, NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(4):e168-e173, 2024. e-Pub 2024. PMID: 38212207.
- Short, NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
- Short, NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol:JCO2301911. e-Pub 2024. PMID: 38277619.
- Short, NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
- Short, NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
- Short, NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
- Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
- Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia 36(12):2817-2826, 2022. e-Pub 2022. PMID: 36261575.
- Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
- Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
- Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
- Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
- Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. e-Pub 2021. PMID: 33780038.
- Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
- Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
- Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. e-Pub 2020. PMID: 33030517.
- Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
- Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
- Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
- Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol 94(2):257-265, 2019. e-Pub 2019. PMID: 30394566.
- Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
- Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
- Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
- Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2018. PMID: 28616864.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28718728.
- Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
- Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
- Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
- Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
- Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
- Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
- Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer 121(21):3869-76, 2015. e-Pub 2015. PMID: 26218678.
- Short NJ, Hayes TG, Bhargava P. Intra-abdominal splenosis mimicking metastatic cancer. Am J Med Sci 341(3):246-9, 2011. e-Pub 2011. PMID: 21446083.
- Short N, Shah C. Muehrcke's lines. Am J Med 123(11):991-2, 2010. e-Pub 2010. PMID: 21035588.
Invited Articles
- Short NJ, Kantarjian H, Jabbour E. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma 65(10):1405-1417, 2024. e-Pub 2024. PMID: 38850572.
- Short NJ, Dillon R. Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Am J Hematol, 2024. e-Pub 2024. PMID: 39319951.
- Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol 17(1):32, 2024. e-Pub 2024. PMID: 38734670.
- Short, NJ, Jabbour E, Kantarjian H. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38485650.
- Short, NJ, Senapati J, Jabbour E. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Curr Hematol Malig Rep 18(6):234-242, 2023. e-Pub 2023. PMID: 37651057.
- Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J 13(1):142, 2023. e-Pub 2023. PMID: 37696819.
- Short, NJ, Kantarjian H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol 10(5):e382-e388, 2023. e-Pub 2023. PMID: 37003279.
- Short NJ, Kantarjian H. Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions. Am J Hematol 97(12):1616-1626, 2022. e-Pub 2022. PMID: 35871436.
- Short, NJ, Jabbour, E. What is the Future of Monoclonal Antibodies in Acute Lymphoblastic Leukemia?. ASCO Dailey News, 2022. e-Pub 2022.
- Short NJ, Kantarjian H, Jabbour E. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22(2):61-66, 2022. e-Pub 2022. PMID: 34561201.
- Short NJ, Dombret H, Adès L, Kantarjian H. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. Cancer J 28(1):29-36, 2022. e-Pub 2022. PMID: 35072371.
- Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. e-Pub 2021. PMID: 34172894.
- Short NJ, Jabbour E. Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S52-S53, 2020. e-Pub 2020. PMID: 32862868.
- Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov 10(4):506-525, 2020. e-Pub 2020. PMID: 32014868.
- Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica 104(8):1532-1541, 2019. e-Pub 2019. PMID: 31273094.
- Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 10:2040620719827310, 2019. e-Pub 2019. PMID: 30800259.
- Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet 392(10147):593-606, 2018. e-Pub 2018. PMID: 30078459.
- Short NJ, Kantarjian H, Pui CH, Goldstone A, Jabbour E. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18(7):439-446, 2018. e-Pub 2018. PMID: 29853276.
- Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 13(2):91-99, 2018. e-Pub 2018. PMID: 29423571.
- Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. Best Pract Res Clin Haematol 30(3):193-200, 2017. e-Pub 2017. PMID: 29050692.
- Short NJ, Jabbour E. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep 19(1):6, 2017. e-Pub 2017. PMID: 28205134.
- Short NJ, Ravandi F. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. Clin Lymphoma Myeloma Leuk 6 Suppl:S25-9, 2016. e-Pub 2016. PMID: 27521321.
- Short NJ, Ravandi F. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. Expert Rev Hematol 9(6):529-34, 2016. e-Pub 2016. PMID: 27158854.
- Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 19(1):82-93, 2014. e-Pub 2014. PMID: 24319019.
Review Articles
- Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, Park J, Shah B, Stock W, Jabbour E. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv 9(6):1442-1451, 2025. e-Pub 2025. PMID: 39853316.
- Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol 9(7):e535-e545, 2022. e-Pub 2022. PMID: 35772432.
- Short NJ, Kantarjian H. When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era. J Clin Oncol:JCO2100960. e-Pub 2021. PMID: 34406793.
- Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. J Clin Oncol:JCO2100067. e-Pub 2021. PMID: 34043455.
Professional Educational Materials
- Short NJ, Connors JM. Bleeding and Thrombosis in Cancer Patients. Clinical Oncology News: Essential Oncoology, 2017.
Editorials
- Short, NJ, Kantarjian, HM, Jabbour, EJ. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?. Expert review of hematology 17(6):189-191, 2024. PMID: 38726703.
- Short NJ, Jabbour E. Counterpoints: Should treatment of chronic myeloid leukemia continue indefinitely?. Clin Adv Hematol Oncol 15(6):489-492, 2017. PMID: 28749909.
- Short NJ, Jabbour E. Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive?. Clin Adv Hematol Oncol 14(11):892-894, 2016. PMID: 27930640.
Abstracts
- Short N, Kantarjian H, Ravandi F, Huang X, Thompson P, Ferrajoli A, Kadia T, Jain N, Alvarado Y, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau S, Konopleva M, Garcia-Manero G, Garris R, Schroeder H, Milton A, Rivera J, Banks G, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, DiNardo C, Daver N, Nguyen D, Yilmaz M, Kadia T, Garcia-Manero G, Issa G, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien K, Borthakur G, Delumpa R, Milton A, Pierce S, Jabbour E, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia T, Khoury J, Jorgensen J, Wang S, Alvarado Y, Burger J, Daver N, Borthakur G, DiNardo C, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda W, Kornblau S, Jacob J, Kwari M, Rausch C, Loiselle C, Milton A, Rivera J, Garris R, O'Brien S, Jabbour E. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour E, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo C, Daver N, Issa G, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien K, Ravandi F, Kadia T, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce S, Waller L, Banks G, Kantarjian H, Cortex J. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva M, Desikan S, Jain N, Ravandi F, Huang X, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, DiNardo C, Thankachan J, Delumpa R, Milton A, Rivera J, Waller L, Garris R, Jabbour E. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Alvarado Y, Burger J, Jain N, Konopleva M, Ravandi F, DiNardo C, Masarova L, Sasaki K, Thompson P, Ferrajoli A, Jacob J, Milton A, Garris R, Jabbour E. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, DiNardo C, Daver N, Nguyen D, Yilmaz M, Kadia T, Garcia-Manero G, Issa G, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien K, Borthakur G, Delumpa R, Milton A, Pierce S, Jabbour E, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Ravandi F, Huang X, Thompson P, Ferrajoli A, Kadia T, Jain N, Alvarado Y, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau S, Konopleva M, Garcia-Manero G, Garris R, Schroeder H, Milton A, Rivera J, Banks G, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia T, Khoury J, Jorgensen J, Wang S, Alvarado Y, Burger J, Daver N, Borthakur G, DiNardo C, Konopleva M, Pemmaraju N, Garcia-Manero G, Wierda W, Kornblau S, Jacob J, Kwari M, Rausch C, Loiselle C, Milton A, Rivera J, Garris R, O'Brien S, Jabbour E. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva M, Desikan S, Jain N, Ravandi F, Huang X, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, DiNardo C, Thankachan J, Delumpa R, Milton A, Rivera J, Waller L, Garris R, Jabbour E. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Desikan S, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour E, Daver N, Jain N, Chien K, Maiti A, Montalban-Bravo G, Kadia T, Kwari M, Kantarjian H, Short N. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour E, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo C, Daver N, Issa G, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien K, Ravandi F, Kadia T, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce S, Waller L, Banks G, Kantarjian H, Cortex J. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Venugopal S, Kadia T, Ravandi F, DiNardo C, Daver N, Borthakur G, Konopleva M, Garcia-Manero G, Montalban-Bravo G, Maiti A, Yilmaz M, Issa G, Chien K, Pierce S, Kantarjian H, Short N. Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Alvarado Y, Burger J, Jain N, Konopleva M, Ravandi F, DiNardo C, Masarova L, Sasaki K, Thompson P, Ferrajoli A, Jacob J, Milton A, Garris R, Jabbour E. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 138(1 (Supp)), 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Combination of Ponatinib and Blinaxtumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study. American Society of Cliical Oncology (ASCO), 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Interim Results of a Phase II Study of Blinatumomab Plus Ponatinib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. EHA, 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Combination of Ponatinib and Blinaxtumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study. American Society of Cliical Oncology (ASCO), 2021. e-Pub 2021.
- Short N, Kantarjian H, Konopleva MY, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvardo Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Interim Results of a Phase II Study of Blinatumomab Plus Ponatinib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. EHA, 2021. e-Pub 2021.
- Short, NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, Patel K, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Jabbour E, Yilmaz M, Issa GC, Andreeff M, Kadia T. Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53¬-Mutated Acute Myeloid Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Kantarjian HM, Ravandi F, Huang X, Ferrajoli A, Kadia TM, Thompson PA, Alvarado Y, Jain N, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau SM, Konopleva M, Garcia-Manero G, Schroeder HM, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien SM, Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Konopleva M, e J, Kadia T, Daver N, Cook R, Jain N, Ravandi F. Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Kantarjian HM, Patel K, Kornblau SM, Jorgensen JL, Wang SA, Konopleva M, Jain N, Kebriaei P, Yilmaz M, Issa GC, Matthews JA, Noor M, Garris R, Ravandi F, Jabbour E. Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Konopleva M, e J, Kadia T, Daver N, Cook R, Jain N, Ravandi F. Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Kantarjian HM, Ravandi F, Huang X, Ferrajoli A, Kadia TM, Thompson PA, Alvarado Y, Jain N, Yilmaz M, Khoury JD, Jorgensen JL, Wang SA, Kornblau SM, Konopleva M, Garcia-Manero G, Schroeder HM, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien SM, Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short, NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, Patel K, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Jabbour E, Yilmaz M, Issa GC, Andreeff M, Kadia T. Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53¬-Mutated Acute Myeloid Leukemia. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Kantarjian HM, Patel K, Kornblau SM, Jorgensen JL, Wang SA, Konopleva M, Jain N, Kebriaei P, Yilmaz M, Issa GC, Matthews JA, Noor M, Garris R, Ravandi F, Jabbour E. Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. American Society of Hematology (ASH), 2020. e-Pub 2020.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Daver N, DiNardo C, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, Khoury J, Jorgensen J, Jain N, Alvarez J, Tippett N, O'Brien S, Jabbour E. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Short NJ, Rafei H, Daver N, Hwang H, Ning J, Cortes J, Jorgensen J, Kadia T, DiNardo C, Wang S, Jabbour E, Popat U, Oran B, Konopleva M, Garcia-Manero G, Borthakur G, Bhalla K, Issa G, Kantarjian H, Ravandi F. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R, Daver N, Pemmaraju N, Khoury J, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien S, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R, Daver N, Pemmaraju N, Khoury J, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien S, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Daver N, DiNardo C, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, Khoury J, Jorgensen J, Jain N, Alvarez J, Tippett N, O'Brien S, Jabbour E. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Short NJ, Rafei H, Daver N, Hwang H, Ning J, Cortes J, Jorgensen J, Kadia T, DiNardo C, Wang S, Jabbour E, Popat U, Oran B, Konopleva M, Garcia-Manero G, Borthakur G, Bhalla K, Issa G, Kantarjian H, Ravandi F. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. American Society of Clinical Oncology, 2019. e-Pub 2019.
- Samra B, Richard-Carpentier G, Ravandi F, Kadia TM, Guerra VA, Daver NG, DiNardo CD, Issa GC, Bose P, Yilmaz M, Ohanian M, Borthakur GM, Garcia-Manero G, Pierce SA, Cortes JE, Kantarjian HM, Short NJ. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood (ASH Annual Meeting Abstracts) 134(1 (Supp)), 2019. e-Pub 2019.
- Short NJ, Garcia-Maner G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II trial. American Society of Hematology 59th Annual Meeting, 2017. e-Pub 2017.
- Short NJ, Garcia-Maner G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II trial. American Society of Hematology 59th Annual Meeting, 2017. e-Pub 2017.
- Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma 58(10):2508-2510, 2017. e-Pub 2017. PMID: 28264600.
- Short NJ, Jabbour E, Ravandi F, Daver N, Pemmaraju N, Thomas DA, Yilmaz M, Kadia T, Sasaki K, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O’Brien S, Kantarjian H. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. American Society of Clinical Oncology, 2017. e-Pub 2017.
- Short NJ, Kantarjian H, O’Brien S, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson P, Cortes J, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. American Society of Clinical Oncology, 2017. e-Pub 2017.
- Short NJ, Kantarjian H, O’Brien S, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson P, Cortes J, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. American Society of Clinical Oncology, 2017. e-Pub 2017.
- Short NJ, Jabbour E, Ravandi F, Daver N, Pemmaraju N, Thomas DA, Yilmaz M, Kadia T, Sasaki K, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O’Brien S, Kantarjian H. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. American Society of Clinical Oncology, 2017. e-Pub 2017.
- Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A phase II trial of omacetaxine mepesuccinate for patients with high-risk myelodysplastic syndrome after failure of hypomethylating agents. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Kantarjian H, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, Marin D, O’Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Jabbour E. Achievement of minimal residual disease negativity by multiparameter flow cytometry is an important therapeutic endpoint in patients with relapsed/refractory B-cell acute lymphoblastic leukemia receiving salvage treatment. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin CC, Khouri MR, Cortes JE, Garris R, O’Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional chromosomal abnormalities in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors: differential outcomes according to type of chromosomal abnormality. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Cortes JE, Garris R, O’Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Ko H, Ravandi F, Thomas D, Garcia-Manero G, Khouri R, Cortes J, Wierda W, Verstovsek S, Estrov Z, Ferrajoli A, Thompson P, Pierce S, Kantarjian H. Outcomes of adult patients with relapsed/refractory Burkitt or Burkitt-like leukemia/lymphoma. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Ravandi F, Cortes JE, Garris R, O’Brien SM, Patel K, Jorgensen JL, Khoury J, Garcia-Manero G, Thomas D, Kantarjian H, Jabbour E. Patterns of relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who achieve complete molecular response with chemotherapy plus a tyrosine kinase inhibitor. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Ravandi F, Huang X, Cortes J, Pemmaraju N, Daver N, Khouri R, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia T, Wierda W, DiNardo C, O’Brien S, Shah SA, Pike A, Brandt M, Kantarjian H, Jabbour E. Updated results of a randomized phase II trial of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. American Society of Clinical Oncology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Ko H, Ravandi F, Thomas D, Garcia-Manero G, Khouri R, Cortes J, Wierda W, Verstovsek S, Estrov Z, Ferrajoli A, Thompson P, Pierce S, Kantarjian H. Outcomes of adult patients with relapsed/refractory Burkitt or Burkitt-like leukemia/lymphoma. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin CC, Khouri MR, Cortes JE, Garris R, O’Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional chromosomal abnormalities in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors: differential outcomes according to type of chromosomal abnormality. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Ravandi F, Cortes JE, Garris R, O’Brien SM, Patel K, Jorgensen JL, Khoury J, Garcia-Manero G, Thomas D, Kantarjian H, Jabbour E. Patterns of relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who achieve complete molecular response with chemotherapy plus a tyrosine kinase inhibitor. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Jabbour E, Cortes JE, Garris R, O’Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A phase II trial of omacetaxine mepesuccinate for patients with high-risk myelodysplastic syndrome after failure of hypomethylating agents. American Society of Hematology, 2016. e-Pub 2016.
- Sasaki K, Kantarjian H, Ravandi F, Thomas D, Daver N, Kadia T, Konopleva M, Jain N, Short NJ, Jeanis V, Moore G, Garris R, Garcia-Manero G, Cortes J, O’Brien S, Jabbour E. Propensity score analysis: frontline therapy with hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. American Society of Clinical Oncology, 2016. e-Pub 2016.
- Short NJ, Kantarjian H, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, Marin D, O’Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Jabbour E. Achievement of minimal residual disease negativity by multiparameter flow cytometry is an important therapeutic endpoint in patients with relapsed/refractory B-cell acute lymphoblastic leukemia receiving salvage treatment. American Society of Hematology, 2016. e-Pub 2016.
- Short NJ, Ravandi F, Huang X, Cortes J, Pemmaraju N, Daver N, Khouri R, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia T, Wierda W, DiNardo C, O’Brien S, Shah SA, Pike A, Brandt M, Kantarjian H, Jabbour E. Updated results of a randomized phase II trial of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. American Society of Clinical Oncology, 2016. e-Pub 2016.
- Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O’Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. American Society of Clinical Oncology, 2015. e-Pub 2015.
- Short NJ, Garcia-Manero G, Montalban Bravo G, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. Low-dose hypomethylating agents are effective in patients with low- or intermediate-1-risk myelodysplastic syndrome: a report on behalf of the MDS Clinical Research Consortium. American Society of Hematology, 2015. e-Pub 2015.
- Short NJ, Kantarjian HM, Jabbour E, O’Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistence of cytogenetic abnormalities at complete remission is not prognostic for relapse-free or overall survival in adult patients with acute lymphoblastic leukemia. American Society of Hematology, 2015. e-Pub 2015.
- Short NJ, Benton CB, Nogueras-Gonzalez G, Hokanson J, Gu L, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes JE, Kantarjian HK, Quintas-Cardama A, Andreeff M. Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction. American Society of Clinical Oncology, 2015. e-Pub 2015.
- Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O’Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. American Society of Clinical Oncology, 2015. e-Pub 2015.
- Short NJ, Kantarjian HM, Jabbour E, O’Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistence of cytogenetic abnormalities at complete remission is not prognostic for relapse-free or overall survival in adult patients with acute lymphoblastic leukemia. American Society of Hematology, 2015. e-Pub 2015.
- Short NJ, Benton CB, Nogueras-Gonzalez G, Hokanson J, Gu L, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes JE, Kantarjian HK, Quintas-Cardama A, Andreeff M. Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction. American Society of Clinical Oncology, 2015. e-Pub 2015.
- Short NJ, Garcia-Manero G, Montalban Bravo G, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. Low-dose hypomethylating agents are effective in patients with low- or intermediate-1-risk myelodysplastic syndrome: a report on behalf of the MDS Clinical Research Consortium. American Society of Hematology, 2015. e-Pub 2015.
Book Chapters
- Chew, S, Short, NJ, Kantarjian, HM, Jabbour, EJ. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, 219-233, 2021.
- Assi R, Short NJ. Malignant Hematological Diseases: Blast Crisis. In: Oncologic Critical Care, 2018.
- Short NJ, Battinelli E. Pharmacologic therapy of anemia. In: Anemia: Pathophysiology, Diagnosis and Management, 2018.
Letters to the Editor
- Short NJ, Ravandi F. 10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply. Lancet Haematol 6: e178, 2019.
- Short NJ, Kantarjian H, Jabbour E. Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer 123: 4935-6, 2017.
Patient Reviews
CV information above last modified October 07, 2025